Kiniksa Pharmaceuticals (KNSA) News Today $23.36 +0.60 (+2.64%) Closing price 04:00 PM EasternExtended Trading$23.37 +0.01 (+0.04%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Raymond James Financial Inc. Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Raymond James Financial Inc. acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 199,953 sMarch 27 at 3:19 AM | marketbeat.comAdvantage Alpha Capital Partners LP Lowers Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Advantage Alpha Capital Partners LP lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 56.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,890 shares of the cMarch 25 at 5:05 AM | marketbeat.comKnights of Columbus Asset Advisors LLC Sells 11,790 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Knights of Columbus Asset Advisors LLC lessened its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 16.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,966 shares of the company's stMarch 24 at 5:43 AM | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Bought by Bank of New York Mellon CorpBank of New York Mellon Corp increased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 33.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,051 shares of the company's stock afterMarch 22, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Up 4.4% - Time to Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 4.4% Higher - Still a Buy?March 21, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 8,879 Shares of StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 8,879 shares of the company's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total value of $205,104.90. Following the completion of the sale, the chief financial officer now directly owns 23,382 shares in the company, valued at $540,124.20. This trade represents a 27.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.March 20, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa Sells 11,464 SharesKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 11,464 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $23.10, for a total transaction of $264,818.40. Following the transaction, the chief financial officer now owns 23,382 shares in the company, valued at $540,124.20. The trade was a 32.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.March 20, 2025 | marketbeat.comMark Ragosa Sells 8,879 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockMarch 20, 2025 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Globeflex Capital L PGlobeflex Capital L P grew its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 217.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,596 shares of the company's stock after purchasingMarch 16, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Connor Clark & Lunn Investment Management Ltd. reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 306,946 shares of the company's stock after selling 17March 16, 2025 | marketbeat.comMichael R. Megna Sells 9,051 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 9,051 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares of the company's stock, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.March 15, 2025 | marketbeat.comMark Ragosa Sells 36,372 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 36,372 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $510,815.50. This represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.March 15, 2025 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells 9,051 Shares of StockMarch 15, 2025 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have been given an average recommendation of "Buy" by the five research firms that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-yearMarch 14, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at CitigroupCitigroup began coverage on Kiniksa Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $40.00 target price for the company.March 14, 2025 | marketbeat.com3 No-Brainer Healthcare Stocks to Buy With $1,000 Right NowMarch 14, 2025 | fool.comCitigroup Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Buy RecommendationMarch 14, 2025 | msn.comKiniksa initiated with a Buy at CitiMarch 13, 2025 | markets.businessinsider.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Essex Investment Management Co. LLCEssex Investment Management Co. LLC lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 13.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,799 shares of the coMarch 10, 2025 | marketbeat.comPrincipal Financial Group Inc. Sells 25,944 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Principal Financial Group Inc. trimmed its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 49.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,907 shares of the company's stock aftMarch 7, 2025 | marketbeat.comKiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan AnalystMarch 6, 2025 | benzinga.comIs Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?March 6, 2025 | msn.comY Intercept Hong Kong Ltd Invests $258,000 in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,050 shares of the company's stock,March 5, 2025 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Up 9.3% - Here's WhyKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 9.3% Higher - Still a Buy?March 3, 2025 | marketbeat.comShort Interest in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Grows By 53.4%Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,960,000 shares, an increase of 53.4% from the January 31st total of 1,930,000 shares. Based on an average daily trading volume, of 463,600 shares, the short-interest ratio is currently 6.4 days.March 3, 2025 | marketbeat.comIs Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now?March 2, 2025 | msn.comLos Angeles Capital Management LLC Has $1.10 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Los Angeles Capital Management LLC lowered its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 44.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 55,528 shares of the company's stock after selliMarch 2, 2025 | marketbeat.comEvercore ISI Remains a Buy on Kiniksa Pharmaceuticals (KNSA)February 28, 2025 | markets.businessinsider.comWedbush Equities Analysts Raise Earnings Estimates for KNSAKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Wedbush boosted their Q1 2025 earnings per share estimates for Kiniksa Pharmaceuticals in a report issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.31 per share for tFebruary 27, 2025 | marketbeat.comKiniksa price target lowered to $30 from $35 at Wells FargoFebruary 26, 2025 | markets.businessinsider.comKiniksa issues updates on abiprubart, KPL-387, mavrilimumabFebruary 26, 2025 | msn.comBig Pipeline Updates From Kiniksa PharmaceuticalsFebruary 25, 2025 | seekingalpha.comKiniksa Pharmaceuticals' (KNSA) "Outperform" Rating Reiterated at WedbushWedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Tuesday.February 25, 2025 | marketbeat.comKiniksa Pharmaceuticals International, plc 2024 Q4 - Results - Earnings Call PresentationFebruary 25, 2025 | seekingalpha.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Announces Earnings ResultsKiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same quarter last year, the company earned $0.35 earnings per share. Kiniksa Pharmaceuticals's quarterly revenue was up 46.9% on a year-over-year basis.February 25, 2025 | marketbeat.comKiniksa to discontinue development of abiprubart in Sjogren’s DiseaseFebruary 25, 2025 | markets.businessinsider.comKiniksa announces development of KPL-387, updated corporate strategyFebruary 25, 2025 | markets.businessinsider.comKiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio ExecutionFebruary 25, 2025 | globenewswire.comKiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate StrategyFebruary 25, 2025 | globenewswire.comKiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025February 20, 2025 | globenewswire.comKiniksa Pharmaceuticals (KNSA) to Release Quarterly Earnings on WednesdayKiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Legato Capital Management LLCLegato Capital Management LLC cut its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 23.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,379 shares of the company's stoFebruary 14, 2025 | marketbeat.comKiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks RemainFebruary 13, 2025 | seekingalpha.comEben Tessari Sells 14,000 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockFebruary 13, 2025 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $273,980.00 in StockKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 14,000 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now owns 81,975 shares of the company's stock, valued at approximately $1,604,250.75. The trade was a 14.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 12, 2025 | marketbeat.comKiniksa Pharmaceuticals COO sells shares worth $273,980February 12, 2025 | msn.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Down 5.4% - Here's WhyKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Down 5.4% - What's Next?February 11, 2025 | marketbeat.comPharma Companies Turn to AI to Speed Up Drug Development, But Hit HurdlesFebruary 10, 2025 | msn.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by BrokeragesShares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have earned a consensus rating of "Buy" from the five brokerages that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 12 month price target among brokeragFebruary 10, 2025 | marketbeat.comSG Americas Securities LLC Takes $355,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)SG Americas Securities LLC bought a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 17,970 shares of the company's stock, valued at approximately $355,000.February 4, 2025 | marketbeat.com Remove Ads Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address KNSA Media Mentions By Week KNSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼1.600.78▲Average Medical News Sentiment KNSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼84▲KNSA Articles Average Week Remove Ads Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News Legend Biotech News Axsome Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News Blueprint Medicines News Krystal Biotech News Nuvalent News Cytokinetics News Verona Pharma News Grifols News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
